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A B S T R A C T
Vancomycin-intermediate Staphylococcus aureus (VISA) and its precursor hetero-VISA (hVISA) were
discovered almost 20 years ago and have continued to be a stumbling block in the chemotherapy of
methicillin-resistant S. aureus (MRSA). Unlike vancomycin resistance mediated by the van gene in
enterococci and staphylococci, VISA is generated by accumulation of mutations. It displays diverse and
intriguing genetic mechanisms underlying its resistance phenotype. Here we make a brief note on our
recent understanding of the genetics of hVISA, VISA and the newly discovered phenotype ‘slow VISA’
(sVISA).
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Infection and Cancer. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).
Contents lists available at ScienceDirect
Journal of Global Antimicrobial Resistance
jo u rn al h om ep age: w ww.els evier .c o m/lo c ate / jg ar* Corresponding author. Tel.: +81 3 5802 1040; fax: +81 3 5684 7830.
E-mail addresses: khiram06@juntendo.ac.jp, khiram@aol.com (K. Hiramatsu).
http://dx.doi.org/10.1016/j.jgar.2014.04.006
2213-7165/ 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Chemotherapy of Infection and Cancer. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
K. Hiramatsu et al. / Journal of Global Antimicrobial Resistance 2 (2014) 213–2242141. Introduction
The ﬁrst clinical vancomycin-intermediate Staphylococcus
aureus (VISA) strain (Mu50) with a vancomycin minimum
inhibitory concentration (MIC) of 8 mg/L and the hetero-VISA
(hVISA) strain (Mu3) with an MIC of 2 mg/L were isolated in 1996
[1,2]. hVISA is the precursor of VISA and is composed of cell
subpopulations with various degrees of vancomycin resistance [2].
They were initially named vancomycin-resistant S. aureus (VRSA)
and hetero-VRSA (hVRSA), respectively, because both of them
caused infection that was clinically refractory to vancomycin
therapy [3]. However, Mu50 and Mu3 were renamed as VISA and
hVISA, respectively, according to contemporary vancomycin
susceptibility criteria in clinical laboratories, which deﬁned
resistance as an MIC  32 mg/L, intermediate resistance as an
MIC of 8 mg/L or 16 mg/L and susceptible as an MIC  4 mg/L.
Subsequently, the criteria were changed to include an MIC of 4 mg/
L in the intermediate group, and 16 mg/L in the resistant group to
reﬂect accumulated clinical experience of frequent vancomycin
therapeutic failure against methicillin-resistant S. aureus (MRSA)
with an MIC of 4 mg/L [4].
The above nomenclature is still incomplete and will remain so
as long as it is based on MIC values alone. Some VISA strains
recorded MICs of 16 mg/L, and even 32 mg/L in the case of ‘slow
VISA’ (sVISA) (see below). Therefore, it would be better to re-deﬁne
the terms VISA and VRSA based on their mechanisms of resistance
and not on the degree of their resistance, i.e. VRSA for strains
whose vancomycin resistance is caused by the horizontally
acquired vanA gene complex [5], and VISA for strains whose
resistance is caused by accumulation of mutations. In the
following, we describe recent advances in our understanding of
the mechanism of resistance in VISA and hVISA as well as sVISA, a
newly identiﬁed category of VISA.
2. Elusive nature of vancomycin susceptibility
2.1. Inoculum effect of vancomycin
Vancomycin is unique in its high-inoculum effect against S.
aureus. The anti-S. aureus activity of vancomycin is greatly
compromised against a high inoculum of bacteria [6]. This feature
of vancomycin is closely associated with the nature of its target of
action. Cell wall peptidoglycan (PG) layers contain many free D-
alanyl-D-alanine residues in the murein components, to which
vancomycin binds with high afﬁnity [7]. These are considered as
‘pseudotargets’ or ‘false targets’ of vancomycin, since binding itself
does not affect the viability of the cell [3]. Real or vital targets of
vancomycin are the lipid–murein monomer precursors on the
cytoplasmic membrane that serve as substrates for transglycosy-
lase [3,7]. Transglycosylase does not use the lipid–murein
monomer precursors bound by vancomycin as substrates. Thus,
vancomycin does not act on the cell-wall synthesis enzyme but on
the substrate for the enzyme. This indirect mode of action makes
vancomycin an inefﬁcient bactericidal agent [3].
Penicillin-binding proteins (PBPs) function to strengthen the
three-dimensional (3D) structure of PG. They cut between the D-
alanyl-D-alanine residues of the stem pentapeptide of a nascent PG
chain, and cross-bridge the penultimate D-alanine to the tip of the
pentaglycine of the neighbouring nascent PG chain [7,8]. In this
way, the cell wall PG gains physical strength and the vancomycin
binding sites decrease. However, S. aureus cells usually have ca.
20% of the PG components uncrosslinked, and there remain ca.
6  106 pseudotargets of vancomycin in the PG layers [3]. Then,
theoretically, 108 S. aureus cells can adsorb 1.4 mg of vancomycin
without losing their viability. This would lead to a great drawback
for vancomycin therapy because this sequestration of vancomycinleads to a signiﬁcant decrease in the effective vancomycin
concentration in the infected tissue of patients. Experimentally,
VISA clinical strain Mu50, having two times thicker and less cross-
linked PG layers than that of usual S. aureus strains, was
demonstrated to adsorb as much as 6.3 mg of vancomycin per
108 cells [9].
2.2. The pitfall of vancomycin susceptibility tests
Since vancomycin has to pass through the PG layers to reach the
cytoplasmic membrane, many molecules are lost before reaching
the real targets. This loss of vancomycin by PG layers becomes
greater if the number of cells increases. The loss is simply caused
by binding of vancomycin to PG, so it does not matter whether the
bacteria are dead or alive. If an abscess is formed in the infected
tissue, it is expected that live bacteria inside the abscess would
never be reached by vancomycin since the antibiotic is consumed
by the cells in the outer layers of the abscess.
This nature of vancomycin makes accurate evaluation of
vancomycin susceptibility difﬁcult. If a large number of S. aureus
cells are inoculated on a vancomycin-containing agar plate, a
substantial amount of vancomycin is adsorbed by the cells and lost
from the surface of the agar. Thus, the effective drug concentration
of the agar is drastically decreased because the high molecular
weight (1449.27 Da) of vancomycin prevents its quick diffusion
across the agar plate. The presence of cell clumps in the dense
inoculum also makes it difﬁcult to allow each cell to be exposed to
equally selective concentrations of vancomycin. A higher inoculum
frequently leads to patchy cell growth even on agar plates
containing much greater concentrations of vancomycin than the
MIC. Therefore, the level of vancomycin resistance must be
carefully evaluated keeping the inoculum size limited per agar
plate. In particular, in the analysis of resistant subpopulations
[population analysis (PA)] for vancomycin, the inoculum size
should not exceed 107 CFU for each vancomycin agar plate of 9 cm
in diameter [10]. Otherwise, the plate will allow patchy growth of
the cells that are susceptible to the nominal concentrations of
vancomycin.
2.3. Population analysis and clinical feature of hVISA infection
Fig. 1 shows the PA curves of hVISA strain Mu3 and VISA strain
Mu50. Mu3-6R-P is a laboratory sVISA strain derived from Mu3,
which will be discussed below. Some subpopulations of Mu3 can
grow on agar plates containing 4 mg/L vancomycin. Thus, the
Mu3 cell population is composed of resistant subpopulations with
various degrees of vancomycin resistance. This was reﬂected in the
clinical course of pneumonia caused by Mu3. When the patient
was treated with vancomycin, the inﬁltrate of the chest radiograph
became faint for the initial 9 days. However, in the next 4 days the
inﬁltrate became dense again despite continued vancomycin
treatment with the same regimen [11]. This characteristic clinical
picture of the infection (initial improvement and subsequent
exacerbation) appears to be a typical pattern of hVISA infection
[12]. Most of the cell population of hVISA are depressed of growth
by the attainable tissue concentrations of vancomycin, presumably
lower than ca. 2–5 mg/L [3], leaving a small number of the VISA
subpopulation to survive vancomycin therapy. During continua-
tion of vancomycin therapy, VISA-converted cells multiply, causing
recurrence of infection.
2.4. The nature of resistant colonies on the population analysis plates
Although the colonies grown on the PA agar plates can be
propagated stably on agar plates containing the same concentra-
tions of vancomycin, their resistance is unstable when the colonies
Fig. 1. Vancomycin-resistant subpopulations of vancomycin-intermediate Staphylococcus aureus (VISA; Mu50), hetero-VISA (hVISA; Mu3) and ‘slow VISA’ (sVISA; Mu3-6R-P).
Mu3, Mu50 and Mu3-6R-P were compared for their distribution of vancomycin-resistant subpopulations as evaluated after various periods of incubation from 48 h up to
144 h. The population curves were drawn after 48 h of incubation according to the standard protocol [2,10]. Bars are used to show the number of colonies that appeared on
each agar plate after 72 h up to 144 h of incubation.
Fig. 2. Nutrient dependence of cell wall thickness and the level of resistance of
vancomycin-intermediate Staphylococcus aureus (VISA) strain Mu50. (A) Mu50 was
grown in brain–heart infusion (BHI) medium, washed twice with resting medium
without glucose (RMg) and then incubated at 37 8C for 2 h with shaking in either
one of the following media: RMg; RM (RMg plus 30 mM D-glucose); or RMgn
[RMg plus 30 mM N-acetylglucosamine (GlcNAc)]. The values given under each
picture are the mean and standard deviation of cell wall thickness (nm). (B) Growth
of Mu50 cells with different cell wall thicknesses in BHI medium with 30 mg/L
vancomycin was monitored by optical densitometry (right vertical axis). The
vancomycin concentration in the medium (left vertical axis) was sequentially
monitored by bioassay (dotted line) [9]. Cells with a thicker cell wall started
growing earlier than those with a thinner cell wall.
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established from the agar plates tend to be lower than those
expected from the nominal vancomycin concentrations of the agar
plates on which the colonies were formed. For example, the strain
established from the colonies formed on the agar plate containing
4 mg/L may record an MIC of 2–4 mg/L instead of expected MIC of
5 mg/L when determined with the MIC value scale with 1 mg/L
increment [10]. We consider this decrease in MIC largely due to the
inoculum effect as described above, and partially due to instability
of certain VISA phenotypes [13]. Therefore, repeated colony
puriﬁcation using agar plates containing the same concentration
of vancomycin, or picking the colonies formed on the agar
containing higher concentrations of vancomycin, e.g. 6 mg/L
instead of 4 mg/L, is necessary to establish VISA strains having a
vancomycin MIC of 4 mg/L.
3. Unique mechanism of vancomycin resistance in VISA
3.1. Afﬁnity trapping of vancomycin by false targets
Binding of vancomycin to non-vital targets in PG is the essence
of vancomycin-intermediate resistance in S. aureus. A thick cell
wall, as observed by transmission electron microscopy (Fig. 2A), is
the cardinal feature of VISA [3,13–16]. In VISA strain Mu50, PG
synthesis is accelerated and a greater amount of glucose is
incorporated into the PG compared with Mu3 and control
vancomycin-susceptible S. aureus (VSSA) strains [16]. Cell wall
thickness is highly inﬂuenced by nutrients in the culture medium.
In a medium rich in the structural components of PG such as
glucose and glutamine, Mu50 produces an abnormally thickened
cell wall (Fig. 2A) [16]. As described below, the extent of thickness
of the PG layers directly correlates with the degree of vancomycin
resistance. Therefore, nutrient dependence of the cell wall
thickness of VISA strains requires special attention in the selection
of media for susceptibility tests. Usually, brain–heart infusion
supports the expression of vancomycin resistance much better
than Mueller–Hinton.With the activated cell-wall synthesis pathway in Mu50, supply
of the precursor metabolites does not appear to catch up with
demand. In agreement with this notion is the structural feature of
Mu50 PG. High-performance liquid chromatography (HPLC)
analysis of the PG structure revealed an increased proportion of
glutamine-non-amidated murein monomer versus glutamine-
amidated murein monomer (as reﬂected in the M9/M4 peak ratio)
in Mu50 cells grown in a regular medium [15], which is a sign of the
Fig. 3. Prolonged time for vancomycin (VCM) to reach the cytoplasmic membrane through the thickened Staphylococcus aureus cell wall. (A) Time course of VCM consumption
compared between Mu50 cells with a thin cell wall (RMg) and thick cell wall (RM). Mu50 cells were incubated in resting medium without glucose (RMg) for thin cell walls
and in resting medium containing glucose (RM) for thick cell walls. Cells were then incubated in RMg containing 30 mg/L VCM. A portion (0.5 mL) of the cell preparations
was taken at selected time intervals to measure VCM consumption and the number of viable cells (see Ref. [9] for details). The arrow indicates slowing of VCM consumption by
thick cell wall. Circles, VCM concentration; squares, cell numbers; open symbols, cells with thin cell walls; solid symbols, cells with thick cell walls. (B) The same experiment
was done using cells pre-treated with lysostaphin. Lysostaphin is a glycylglycine endopeptidase that speciﬁcally cleaves the pentaglycine cross-bridges of peptidoglycan (PG)
without cutting off the VCM binding targets D-alanyl-D-alanine residues from the stem pentapeptide. Treated cells consumed amounts of VCM comparable with those
consumed by intact PG (A), whereas slowing of VCM consumption observed with intact PG was lost (denoted by an arrow). , VCM consumption by Mu50 with a thin cell wall;
~, VCM consumption by Mu50 with a thick cell wall.
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amine group to the murein monomer. Coincidentally, glutamine-
non-amidated murein monomer is a poor substrate for PBPs [17].
As a result, a lower rate of PG cross-bridging was observed by HPLC
analysis (lowered dimer/monomer ratio) [16]. This further
contributed to the increase of free D-alanyl-D-alanine residues in
the PG layers and increased consumption of vancomycin.
Furthermore, by another curious coincidence, the non-amidated
muropeptide happened to have a greater binding afﬁnity to
vancomycin than the amidated muropeptide [16]. These observa-
tions correlated well with the experimental data that Mu50
consumes 2.8 times more vancomycin in its cell wall than VSSA
strains [16].
Fig. 2B illustrates that VISA strain Mu50 with a vancomycin MIC
of 8 mg/L can grow in medium containing as high as 30 mg/L
vancomycin [13]. When the concentration of vancomycin was
monitored by bioassay, a signiﬁcant drop in the concentration was
observed from 30 mg/L to ca. 16–17 mg/L within a few minutes of
addition of the cells to the medium. This is due to the rapid
adsorption of vancomycin to the cell wall PG of Mu50. The
vancomycin concentration gradually decreased before the cells
started to re-grow. It is noted that prior to the growth initiation of
Mu50 cells, the concentration of vancomycin dropped to <10 mg/
L. This decline of vancomycin concentration is due to the
sequestration of the drug by the false targets in PG of Mu50.
The vancomycin MIC of the re-grown Mu50 cells was the same as
that of the inoculum. This clearly demonstrates the ‘inoculum
effect’ in S. aureus susceptibility to vancomycin [13].
3.2. Clogging of the peptidoglycan mesh and prolonged time for
vancomycin to reach the cytoplasmic membrane
When VISA cells are exposed to vancomycin, their PG layers
adsorb a huge number of vancomycin molecules as described
above. As a result, bound vancomycin molecules obliterate the PGmesh structure and prevent further passage of vancomycin
molecules from outside of the cell. This ‘clogging effect’ is clearly
observed in Fig. 3. Fig. 3A shows the time-dependent change in
vancomycin concentration of the medium inoculated with ca.
5  108 cells with thick and thin PG layers. In less than 5 min,
15 mg/L vancomycin was adsorbed by both cells, after which no
more decrease was observed with cells with thin PG layers.
Complete saturation of vancomycin binding targets in PG is
achieved. In contrast, cells with thick PG continued adsorbing
vancomycin from the culture medium, but the rate of decrease in
vancomycin concentration was blunted after 5 min and gradually
reached saturation (denoted by an arrow in Fig. 3A). The thick cell
wall ﬁnally adsorbed 25 mg/L vancomycin (Fig. 3A). Slowing of the
decrease in vancomycin concentration was lost by brief treatment
of the cells with lysostaphin, which breaks the PG mesh and allows
vancomycin to penetrate the entire PG layer without hindrance
(Fig. 3B). The more critical sequel of clogging is observed in Fig. 3A,
in which the timing of saturation of thick PG layers is delayed by
20–40 min, which is almost comparable with the doubling time of
S. aureus. This signiﬁes that S. aureus cells would continue
producing PG during the time delay and provide new PG layers
from beneath the older PG layers. In this way, with thickened PG
layers, vancomycin cannot completely inhibit PG synthesis no
matter how high a dose of vancomycin is used. This is another
strategy of VISA. PG now works as a shield for vancomycin
penetration, like the outer membrane of Gram-negative bacteria.
4. Emergence of hVISA and selective pressure
4.1. ‘Regulator mutations’ to generate hVISA: vraUTSR, walKR and
graRS
Evidence is accumulating for the view that vancomycin
resistance in VISA is caused by altered cell wall structure and
metabolism. Since S. aureus cell wall synthesis is regulated by
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strains carry various mutations in the regulator genes associated
with cell wall biosynthesis [12]. Whole-genome sequencing and
microarray analysis of Mu50 identiﬁed the vraSR two-component
regulatory system (TCRS) whose transcriptional upregulation is
responsible for the raised vancomycin resistance of Mu50 [18–20].
In Mu50 (and also in Mu3), the sensor kinase gene vraS was
constitutively activated by the incorporated mutation vraS(I5N).
The mutated VraS in turn activated the cognate response regulator
VraR and raised expression of the genes encoding several key
enzymes of cell wall biogenesis such as murZ, pbp2, sgtB, tarA, fmtA
and lcpC (SA2103) [20,21]. Experimental introduction of the
mutation vraS(I5N) as well as of another experimentally obtained
mutation vraS(S329L) into VSSA strain N315DIP conferred an
hVISA phenotype on the strain [21]. The mutation vraS(I5N) is
carried by many VISA strains isolated from various districts of
Japan [2,22–24], indicating clonal spread of Mu3 throughout Japan.
Recently, vraSR is regarded as part of a four-membered operon,
vraU–vraT (or yvqF)–vraS–vraR. vraT is reported to be essential for
vraSR function as the upregulator of cell wall synthesis [25,26]. The
vraT(Y220C) mutation was shown to activate vraSR and raise both
methicillin and vancomycin resistance [26]. Another mutation
[vraT(T125I)] is also shown to raise vancomycin and imipenemTable 1
rpoB and regulator gene mutations in clinical vancomycin-intermediate Staphylococcus
Phenotype NARSA
no.
Strain name Nationality DT
(min)
rpoB
sequence
VAN
(mg/
hVISA NRS2 Mu3 Japan 36.9 wt 2 
sVISA Mu3-6R-P In vitro 62.2 R512P 12 
VISA NRS1 Mu50 Japan 36.5 H481Y 8 
VISA NRS29 HIP09735 USA 53.8 Y737F 4 
VISA NRS65 LY-1999-03 Oman 49.3 wt 4 
VISA JCSC7203 Thailand 34.8 H481N, S529L 4 
VISA NRS22 HIP07930 USA 47.5 D320N 4 
VISA JCSC7219 Thailand 28.8 H481N, S529L 4 
VISA JCSC7221 Thailand 31.5 wt 4 
VISA NRS12 SA MER-S6 France 29.2 wt 8 
VISA NRS13 SA MER-S12 France 33.5 wt 4 
VISA NRS18 HIP06854 USA 30.2 wt 4 
VISA NRS74 HIP10267 USA 44.8 D471V, A473S,
A477S, E478D
4 
VISA NRS403 HIP13057 USA 36.1 H481Y 4 
VISA NRS21 HIP07920c USA 39.5 R484H, F1075L 4 
VISA NRS23 HIP08926 USA 33.3 wt 4 
VISA NRS24 HIP09143 USA 33.0 wt 4 
VISA NRS26 HIP09313 USA 41.6 wt 4 
VISA NRS27 HIP09433 USA 31.9 D320N 4 
VISA NRS28 HIP09662 USA 41.0 D471N, S486L 4 
VISA NRS49 AMC11094d Korea 33.8 wt 8 
VISA NRS51 HIP09740 USA 27.0 H481D 6 
VISA NRS52 HIP09737 USA 28.9 H481D 4 
VISA NRS63 LY-1999-01 Oman 32.4 R406S 4 
VISA NRS14 SA MER-S20 France 36.1 wt 4 
VISA NRS17 HIP06297 (PC) USA 36.4 Q468L 8 
VISA NRS73 HIP10540 USA 32.6 V135A, A477V 4 
VISA NRS118 NRS118 USA 29.4 H481N, S529L 8 
VISA NRS76 NRS76 USA 28.8 wt 8 
VISA NRS79 NRS79 USA 27.4 H481R 8 
VISA NRS126 NRS126 USA 46.2 H481N 4 
VISA NRS272 P1V44c Belgium 46.7 H481N, S529L,
E792G, F1075L
16 
VISA NRS402 HIP12864c USA 53.1 P519L 4 
VISA NRS404 HIP13036 USA 31.9 wt 8 
VISA NRS3 MI USA 39.1 R140S 8 
hVISA, hetero-VISA; sVISA, ‘slow VISA’; DT, doubling time; VAN, vancomycin; MIC, min
a Susceptible (S), MIC  1 mg/L; resistant (R), MIC > 1 mg/L.
b vraT data are based on Ref. [23].
c sVISA was identiﬁed in the stored culture of the strain.
d AMC11094 from Korea possesses the vraR(A113V) mutation.MICs [23]. This cross-resistance between vancomycin and b-
lactams through activation of the vraSR TCRS has a historical
implication in the emergence of VISA from MRSA in Japan [22].
Acquisition of homogeneously high b-lactam resistance by hetero-
MRSA (see below) appears to have prepared the way for Japanese
MRSA to conquer vancomycin as well.
The vraUTSR operon is frequently mutated in clinical VISA and
hVISA strains (Table 1). Of 33 VISA strains, 14 (42.4%) possessed
mutations in either one of the three genes vraT, vraS and vraR. In
Japan, however, the vraTSR mutation frequency among 86 S. aureus
clinical strains with reduced teicoplanin susceptibility (teicoplanin
MIC  2 mg/L; equivalent to hVISA or ‘pre-hVISA’ described below)
was as high as 67.4% (58 strains) [23]. We found that the
development of hVISA clinical strains among MRSA strains in Japan
occurred before the introduction of vancomycin into clinical use
[22]. Since injectable vancomycin was not introduced in Japan
until 1991, clinical use of potent b-lactam antibiotics such as
imipenem, cefmetazole and ﬂomoxef was the national trend to
cope with MRSA infection in the 1980s [27]. We also found that
hVISA was generated in vitro by selecting a hetero-MRSA strain DIP
with imipenem [8,21], and that the appearance rate of hVISA from
DIP was much higher with imipenem than with vancomycin as a
selective agent (2.0  105 vs. 3.6  107) [21]. aureus (VISA) strains worldwide.
 MIC
L)
RIF
sensitivitya
Sequence of selected genesb
vraT vraS msrR graR walK
S wt I5N E146K wt wt
S wt I5N E146K wt wt
R wt I5N E146K N197S wt
S wt wt wt wt A468T
S wt wt K312R wt N48K, R222K, A468T
R nt wt K312R D68Q R222K, S437F, A468T
S wt G9V E146D wt wt
R nt wt K31R wt R222K, A468T
S nt wt wt wt wt
S wt wt wt wt wt
S wt wt wt wt wt
S wt wt wt wt T492K
R H164R wt wt T11A wt
R wt wt wt E15K R282C
R wt wt wt wt wt
S wt wt wt wt R222I, T492K
S P126S wt wt wt wt
S wt P327S wt wt L10F, S437T
S wt G9V E146D wt V1454G
R wt wt wt wt Ins.433N, 434D
S wt wt wt wt wt
R wt wt wt wt V380I
R wt wt wt wt G275V
S wt wt K312R wt N48K. R222K, A468T
S wt wt wt wt wt
R W119R wt wt wt A567D
R L85F wt wt wt wt
R wt wt wt wt F330S
S wt A314V wt wt A243T
R A151T wt wt wt D496N
R wt wt wt wt wt
R wt wt wt wt wt
R H164R wt wt wt wt
S wt T104A wt wt wt
S G32D wt wt wt V494L
imum inhibitory concentration; RIF, rifampicin; wt, wild-type; nt, not tested.
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walK (yycG/vicK) is a sensor histidine kinase and walR (yycF/vicR) is
the cognate response regulator. The TCRS is supposed to be the
regulator of cell wall metabolism, including expression of
autolysins [28–31]. Introduction of a walK mutation into VSSA
strain N315LR5 raised vancomycin resistance from 1 mg/L to 3 mg/
L and signiﬁcantly depressed Triton X-100-induced autolysis [29].
As many as 18 (54.5%) of 33 tested VISA strains possessed
mutations in the walK gene (Table 1).
Mutation in the response regulator gene graR(N197S) is
present in Mu50 [32]. In another clinical MRSA strain, a
mutation in the sensor kinase gene graS(T136I) was demon-
strated to confer an hVISA phenotype on a VSSA strain [33]. In
the Mu50 chromosome, graR(N197S) is one of the nine non-
synonymous mutations compared with the Mu3 chromosome
[32]. Introduction of graR(N197S) on a multiple-copy plasmid
converted Mu3 into VISA with an MIC of 4 mg/L. However,
introduction of graR(N197S) into Mu3 as a single copy by gene
replacement raised the vancomycin MIC slightly from 2 mg/L to
3 mg/L, i.e. to the degree of resistance of hVISA. Conversion to
VISA was ﬁnally achieved by subsequent introduction of an rpoB
mutation. The rpoB gene encodes the b subunit of RNA
polymerase (see below). Introduction of the graR mutation
enhanced gene expression of the ABC transporter genes vraDE-
SAS091, vraFG and mprF [32,34]. mprF encodes phosphatidyl-
glycerol lysyltransferase that modiﬁes membrane phosphati-
dylglycerol with L-lysine [35]. The graRS genes together with
vraFG and the adjacent orf graX are proposed to constitute the
ﬁve-component system graXRS–vraFG to sense cationic antimi-
crobial peptides [36]. Although rarely represented in clinical
VISA strains, graRS mutation is another regulator mutation that
could convert VSSA into hVISA [33].Fig. 4. Effect of individual mutations towards the development of vancomycin-intermedia
introduced into vancomycin-susceptible S. aureus (VSSA) strain N315DIP and their resis
subpopulations with reduced vancomycin susceptibility. Those one-step-mutated stra
reconstituted the VISA phenotype of Mu50 in VSSA strain N315DIP. 
vraS(S329L)msrR(E146K)graR(N197S); and DIP4, DIP-vraS(S329L)msrR(E146K)graR(N194.2. rpoB mutation as a ‘regulatory’ mutation in hVISA phenotype
acquisition
The most prevalent mutations in VISA clinical strains were
those in the rpoB gene, which were carried by 21 (63.6%) VISA
strains (Table 1). Although rpoB is not a regulator gene, its
mutation drastically changes the transcription proﬁle of the cell
much more than any of the regulator mutations [37]. We therefore
regarded rpoB mutation as a ‘regulatory mutation’ [34,38].
As many as 29 (87.9%) of the 33 tested VISA strains possessed
mutations in either one of the three genetic loci rpoB, walRK and
vraUTSR (Table 1). Considering the low frequency of occurrence of
spontaneous back-mutation, the initial chromosome mutation
towards a VISA phenotype acquisition would remain in the
chromosome of established VISA clinical strains; therefore it
would be plausible to consider that the mutations in rpoB, walRK
and vraUTSR are the ﬁrst-step mutations placing a VSSA onto the
path towards VISA. In this regard, it is interesting that vancomycin
is not the only selective pressure for the generation of hVISA. Use of
non-glycopeptide antibiotics such as rifampicin, daptomycin and
b-lactams may serve as selective pressures for the emergence of
hVISA in the hospital by mutating rpoB [39], walRK [30,40,41] and
vraUTSR [20–22], respectively.
As shown in Fig. 4A, PA curves of DIP-derived strains introduced
with vraS(S329L), walK(V494L), graR(N197S) and rpoB(H481Y) as a
single mutation acquired small subpopulations of cells capable of
growth in the presence of 2–4 mg/L vancomycin. Therefore, all of
the tested mutations possessed the potential to raise vancomycin
resistance as a single mutation. However, none, even the vraS
mutation, formed as many colonies as Mu3 on the agar plate with
4 mg/L vancomycin. To distinguish them from hVISA, we designate
those strains with reduced susceptibility to vancomycinte Staphylococcus aureus (VISA). (A) Regulator mutations and an rpoB mutation were
tant subpopulations were analysed. Note that each mutation developed only small
ins may well be called ‘pre-hVISA’. (B) Sequential introduction of four mutations
DIP1, DIP-vraS(S329L); DIP2, DIP-vraS(S329L)msrR(E146K); DIP3, DIP-
7S)rpoB(H481Y).
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cells capable of growth on the agar plate containing 4 mg/L
vancomycin. The pre-hVISA strains may be correlated with the
‘MIC creep’ phenomenon observed in hospitals where anti-MRSA
chemotherapy is frequently implemented [42].
4.3. Multistep generation of hVISA
Two or more regulator or regulatory mutations may be
required for clinical VSSA to become hVISA, which is deﬁned as
the ability to generate colonies at a frequency of 1  106 on the
agar containing 4 mg/L vancomycin [2]. In the case of Mu3, we
found that another mutation, msrR(E146K), was required in
addition to vraS(I5N) to acquire an hVISA phenotype (Katayama
Y, unpublished data). The ﬁrst-step mutation vraS(I5N) or
vraS(S329L) converted DIP (vancomycin MIC = 1 mg/L) into
pre-hVISA strain DIP1 with an MIC of 2 mg/L. When msrR(E146K)
was introduced as the second mutation, the strain was converted
to hVISA strain DIP2 with a raised MIC of 3 mg/L (Fig. 4B). The
shape of the population curve of DIP2, or DIPvraS(S329L)msr-
R(E146K), was now equivalent to that of Mu3 (Fig. 4B). The
msrR(E146K) mutation was previously shown to raise imipenem
susceptibility and teicoplanin resistance when overexpressed in
VSSA strain N315 [43]. We then noticed that the mutation was
shared by Mu3 and Mu50. The msrR gene is present on the S.
aureus chromosome as one of the three paralogues encoding
proteins of the LytR–CpsA–Psr (LCP) family [44]. The msrR (or
lcpA) and the other two lcp genes lcpB and lcpC are proposed to
function in the last stage of wall teichoic acid (WTA) synthesis,
namely attachment of teichoic acid to cell wall PG [44,45]. WTA is
proposed to control autolysis of S. aureus cells through stabilisa-
tion of autolysin [46]. However, it remains to be elucidated how
the altered MsrR in Mu3 and Mu50 contributes to raised
vancomycin resistance.
5. hVISA to VISA conversion
5.1. Conversion of Mu3 to Mu50
There are two levels in VISA: ‘high-level’ VISA with vancomycin
MICs of 8 mg/L; and ‘low-level’ VISA with MICs of 4 mg/L. Mu50
(NRS1) [1] and MI (NRS3) [47] represent high-level VISA, whereas
the majority of clinical VISA strains are low-level VISA (Table 1). As
illustrated in Fig. 4B, introduction of graR(N197S) raised vanco-
mycin resistance of hVISA strain Mu3 to the level of a low-level
VISA, and subsequent introduction of rpoB(H481Y) converted it
into high-level VISA indistinguishable from Mu50 [34].
Subsequently, the VISA phenotype of Mu50 was successfully
reconstituted in VSSA strain N315DIP by sequentially introducing
four mutations, i.e. vraS(S329L), msrR(E146K), graR(N197S) and
rpoB(H481Y) (Katayama Y, unpublished data) (Fig. 4B).
However, we were not convinced with the idea that combina-
tion of graR and rpoB mutations was the only way for Mu3 to
become high-level VISA. To obtain a more comprehensive view on
the genetic events underlying hVISA-to-VISA conversion, we
established 45 high-level VISA strains by selecting Mu3 and its
related hVISA strains with 6 mg/L vancomycin and determined
their whole genome sequences [38].
5.2. Extremely diverse genetic mechanisms for hVISA-to-VISA
phenotypic conversion
VISA is generated by spontaneous mutation from hVISA at a
frequency of 106 [3,48,49]. Since the usual appearance rate for a
spontaneous mutation is ca. 108–109, such a high incidence of
emergence of VISA from hVISA indicates the presence of greatnumbers of alternative mutations. The whole-genome sequences
of 45 VISA-converted mutant strains revealed a surprising result
that each converted strain had one to four mutations, but no two
strains shared the same mutation [38]. Table 2 shows the list of
non-synonymous single mutation found in 32 of the 45 VISA-
converted strains. Each strain carried a unique mutation in 1 of the
20 genes. Therefore, those genes listed in Table 2 were considered
to have a direct contribution to the hVISA-to-VISA phenotypic
conversion as a single determinant. By far the most frequently
affected genes were rpoB and rpoC in six strains, cmk in another six
strains, followed by tarO in three strains [38]. They affected various
cellular processes and metabolic pathways of the cell, and ﬁve of
them were reported previously in association with raised
vancomycin resistance, including SAHV_1209 encoding PP2C
phosphatase [50], pbp4 [51], rpoB [34,39,52], rpoC [53] and walK
[28–30,54]. Reduction in PBP4 activity decreases PG cross-linkages
and thus increases the number of false targets of vancomycin. PP2C
phosphatase and the walKR TCRS are considered to be associated
with cell wall metabolism and the control of autolysis [50,55].
Accelerated cell wall synthesis and decreased autolysis are two
alternative ways to thicken cell wall PG layers. In this regard, it is
also noteworthy that the orf SAHV_1760 encoding putative
autolysin is among the singly mutated gene list (Table 2).
As shown in Table 1, rpoB mutation is frequently found in
clinical VISA strains. In a separate experiment using nine Japanese
clinical MRSA strains, we established 90 rifampicin-resistant
mutant strains. By testing their susceptibility to vancomycin, we
found that 86 (95.6%) of 90 rifampicin-selected mutant strains
showed decreased vancomycin susceptibilities [39]. Besides rpoB
encoding the b subunit of the RNA polymerase holoenzyme, genes
encoding the other subunits of RNA polymerase holoenzyme, rpoC,
as a unique mutation, and rpoD (sigA) and rpoA, as one of the double
mutations, respectively, were also found in the 45 VISA-converted
strains [38]. Therefore, the structural change in RNA polymerase
holoenzyme itself appears to raise vancomycin resistance through
the alteration of cell physiology and metabolism.
Of the 20 mutations, 15 were newly identiﬁed in the above
experiment [38]. Among them the most frequently found was cmk
encoding cytidylate kinase. The enzyme catalyses the formation of
cytidine diphosphate (CDP). The mutation decreased the function
of cmk (Matsuo M, unpublished data). cmk dysfunction is
considered to result in the depression of not only DNA/RNA
synthesis but also WTA synthesis, since supply of CDP–glycerol is
required for the synthesis of WTA [56]. Coincidentally, a total of
six other strains had mutations in the genes of the WTA
biosynthesis pathway (Table 2). Together with cmk mutation,
as many as 12 (37.5%) of the mutant strains may have depressed
WTA synthesis. In Gram-positive bacteria, the structural compo-
nents of PG and WTA are synthesised on the membrane carrier
undecaprenyl phosphate [57]. Since a limited number of lipid
carriers are available in the membrane [58], a depressed teichoic
acid synthesis pathway may provide an advantage for the
synthesis of PG components. A depressed teichoic acid synthesis
pathway and cmk dysfunction may help raise vancomycin
resistance by allowing the PG synthesis enzymes to use more
membrane carrier lipids.
It should be noted that the above experiment was done using
Mu3 and its derivative strains [38]. Therefore, the cell wall PG
synthesis pathways in the recipient strains were already activated
by vraS(I5N) mutation [20]. This may be the reason why mutations
were not observed in the vraTSR regulatory system in the
experiment. Another mutation in walKR TCRS frequently observed
in clinical VISA strains was not prevalent either in the experiment;
only one strain carried the mutation (Table 2). It is possible that
at least part of the effects of vraSR mutation is redundant with
that of walKR mutation in the control of cell wall metabolism.
Table 2
Functional categorisation of genes that are singly mutated in 32 vancomycin-intermediate Staphylococcus aureus (VISA)-converted strains.
Mutated genes Description The location of Mutation and  AA Change
a pathways
Number of
strains (%)
pbp4 Penicillin binding protein 4 S140N PG synthesis 1
SAHV_1760 cell wall hydrolase W200C PG degradation (Autolysis) 1
tarO (=llm or tagO) Wall teichoic acid biosynthesis protein  TarO P94L 169R F205L Wall teichoic acid synthesis
tarA (=tagA) Wall teichoic acid biosynthesis protein  TagA (10bp upstream of the orf ) Wall teichoic acid synthesis 6 (19%)
SAHV_0256 (tarL) Wall teichoic acid biosynthesis protein  TagL W13R S224Y Wall teichoic acid synthesis
gtaB UTP-glucose-1-phosphate uridyltransferase Q220* Lipoteichoic acid synthesis 1
rpoB  subunit of RNA polymerase R406S T480M G540V S746Y A1085V Transcription
rpoC ' subunit of RNA polymerase P440L Transcription
walK or vicK Involved in the regulation of autolysin genes Q216E Transcription regulation 1
cmk Cytidylate kinase A20G A24V I128N G129V G201V Pyrimidine metabolism 6 (19%)
(13bp upstream of cmk)  
pykA Pyruvate kinase P12S Glycolysis glucose  pyruvate
Purine nucleotide biosynthesis
 1
SAHV_1392 Acylphosphatase G14R Pyruvate metabolism (Acetyl-P Acetate) 1
rpsU Small subunit ribosomal protein S21 E31* Protein synthesis 1
trpC Tryptophan biosynthesis K31N Amino acid synthesis 1
ureD Urease accessory protein V151I Urea degradation 1
SAHV_1209 (pp2c) Protein phosphatase 2C G148(VKLRRKKHLHIHNVILLRR*)b Serine/threonine phosphatase (Autolysis) 1
SAHV_0372 Hypothetical protein T3I Unknown function 1
SAHV_0612 Hypothetical protein V93F Unknown function 1
SAHV_0741 Hypothetical protein G93D Unknown function 1
SAHV_2101 putative hemK family modification methylase G121R Unknown function 1
6 (19%)
PG, peptidoglycan; WTA, wall teichoic acid.
*Denotes a stop codon.
aThe letters in parenthesis denote the amino acid sequences generated by a frameshift mutation.
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5.3. Pleiotropic effects of rpoB mutations
Not all rpoB mutations contribute to raised resistance to
vancomycin. Such rpoB mutations as rpoB(S464P), rpoB(Q468R)
and rpoB(Q468K) raised rifampicin resistance of the mutants but
did not raise their vancomycin resistance appreciably [34]. Fig. 5
shows the location and amino acid substitution of rpoB mutations
found in various categories of S. aureus strains. The mutations
found in clinical strains are described under the scheme of the rpoB
gene, and those generated in the laboratory are described above
the scheme. All of the rifampicin-resistant VISA clinical strains
possessed mutations within the rifampicin resistance-determining
region (RRDR). Six strains were rifampicin-susceptible VISA strains
(MIC < 1 mg/L) whose mutations were found outside of the RRDR
of the rpoB gene (Table 1 and Fig. 5). Such strains having mutation
outside the RRDR can be easily obtained in vitro from hVISA strain
Mu3 by selection with vancomycin, but not with rifampicin. Such
strains tend to have higher levels of vancomycin resistance than
those selected by rifampicin [34]. For example, laboratory-derived
mutant strains with rpoB(T480M), rpoB(R503H) and rpoB(S746Y)
possessed vancomycin MICs of 7, 9 and 9 mg/L, respectively. These
values were signiﬁcantly higher than 4–5 mg/L of the mutants with
rpoB(H481Y) and other RRDR mutations [34].rpoB mutations affect
susceptibility of not only rifampicin and vancomycin but also of
other categories of antibiotics. Depending on the location and
kinds of amino acid substitution, rpoB mutations cause a variety of
phenotypic changes. Especially notable are susceptibilities to
vancomycin, daptomycin and linezolid (Fig. 5). Daptomycin and
vancomycin MICs are positively correlated [32,40,41,52]. In Mu50,
graR(N197S) mutation appears to have raised daptomycin resis-
tance by increasing the positive charge of the cell surface throughenhanced expression of the mprF gene [32,35]. rpoB-mediated
dual resistance to vancomycin and daptomycin was ﬁrst
demonstrated in laboratory strain DIP-10*3d1 that acquired
reduced susceptibility to both antibiotics after serial daptomycin
selection. A single mutation, rpoB(A621E), was responsible for the
dual resistance phenotype [52]. This indicated that multiple
cellular phenotypes separately controlled by independent reg-
ulators may be altered by a single rpoB mutation. We also noticed a
negative correlation between vancomycin MICs and linezolid
MICs among clinical VISA strains [60]. Now we found that certain
rpoB mutations represented by rpoB(S746F) increase linezolid
susceptibility and decrease vancomycin susceptibility at the same
time [34].
Some rpoB mutations also have a profound inﬂuence on
methicillin resistance [61]. Expression of the methicillin resistance
gene mecA is not enough for S. aureus cells to express high-level
methicillin resistance (deﬁned as an MIC > 128 mg/L for oxacillin or
>4 mg/L for imipenem). Acquisition of certain chromosomal
mutations (chr*) was known to be required to convert the mecA-
carrying S. aureus into highly methicillin-resistant S. aureus or
homogeneously methicillin-resistant S. aureus (homo-MRSA).
Without chr*, S. aureus stays as heterogeneously methicillin-
resistant S. aureus (hetero-MRSA). Curiously, the mutated vraS gene
of Mu3 causing an hVISA phenotype turned out to be one of the chr*
mutations [19,20]. The mutation raised both methicillin and
vancomycin resistance by activating cell wall PG synthesis
[20,21]. Such dual activity was also ascribed to several rpoB
mutations (Fig. 5) in which two mutations, rpoB(R512P) and
rpoB(A621E), were conﬁrmed to have the dual activity by gene
replacement experiments. Thus, rpoB(A621E) was found to have a
triple activity on methicillin, vancomycin and daptomycin suscep-
tibilities. On the other hand, recently identiﬁed rpoB mutation
rpoB(I967N) acted as chr* but did not inﬂuence vancomycin
susceptibility [61].
Fig. 5. rpoB mutation and antibiotic resistance phenotype. Mutations found in laboratory-derived Staphylococcus aureus strains are given above the linear scheme of the rpoB
gene; those of clinical strains are given under the scheme. Mutations whose direct contribution to the resistance phenotype is genetically proven are in red boxes. Names of
the vancomycin-intermediate S. aureus (VISA) strains carrying the mutations are either in Table 1 or in the cited references. References for the strains are given in brackets.
Otherwise, the names of the strains are given in parentheses. Series of strains DIP-RIF are DIP-derived in vitro strains selected with 0.125 mg/L rifampicin (Katayama Y,
unpublished data). Dap-R, daptomycin-resistant; Lin-S, linezolid-susceptible; homo-MR, homogeneously methicillin-resistant; hVISA, hetero-VISA; sVISA, ‘slow VISA’; MSSA,
methicillin-susceptible S. aureus; RRDR, rifampicin resistance-determining region. E-MRSA (Eagle-type MRSA) is a class of homo-MRSA characteristically resistant to high
concentrations of methicillin but susceptible to lower concentrations of methicillin [59,61]. All of the sVISA strains listed are derived from Mu3 by selection with 6 mg/L
vancomycin.
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resistance phenotype
In PA, hVISA produces VISA, which is observed as a colony
formed on the vancomycin-containing agar plates within the
incubation time of 48 h [10]. However, we noticed formation of
new colonies on the plates left beyond 2 days of incubation at 37 8C
(Fig. 1). Almost equal or an even greater number of colonies
appeared from the third day (72 h) to the sixth day (144 h) of
incubation. On drug-free agar plates they formed pinpoint
colonies. However, they rapidly generated small or large colonies
during drug-free propagation (Fig. 6). The strains established from
pinpoint colonies exhibited degrees of vancomycin resistance
equal to or greater than that of extant VISA strains (Table 3). Since
the strains grew extremely slowly, we designated them ‘slow VISA’
(sVISA). The representative strain Mu3-6R-P was further studied
and was compared with VISA strain Mu50. Mu3-6R-P had a
doubling time (DT) of 62.2 min, which was extremely prolonged
compared with 37.1 min for VISA strain Mu50. Otherwise, Mu3-
6R-P had the features of a VISA phenotype, i.e. thickened cell wall
and reduced autolytic activity (Table 3). The great difference of
Mu3-6R-P with extant VISA strains was an extremely prolonged
DT and instability of the VISA phenotype and colony morphology.
It generated large colonies at a frequency of 3  107 during
overnight drug-free cultivation. The large colonies were found to
have returned to hVISA, grew fast, and overgrew the culture by thesixth day of serial daily passage: >99.9% of the cell population
formed large colonies. All 28 strains established from the Mu3-
derived colonies that appeared after 72 h incubation on agar plates
with 6 mg/L vancomycin shared the sVISA features, i.e. prolonged
DT, high vancomycin resistance (MIC  6 mg/L) and unstable
expression of the phenotype (Table 3).
6.1. Biological and clinical signiﬁcance of sVISA
The emergence of sVISA strains appears to have a special
biological meaning. Since they can resist greater concentrations of
vancomycin than extant VISA, they would serve as temporary
shelters for hVISA to survive intensive vancomycin therapy. When
vancomycin therapy is over, sVISA can revert to hVISA and may
cause recurrence of infection.
The immediate consequence of this phenomenon would be the
rare visibility of VISA in the clinical laboratory. Extant VISA with a
stable phenotype may be identiﬁed in patient’s samples after or
even before the treatment of infections, but sVISA would not be
readily seen on the vancomycin agar plates before 2 days of
incubation. However, careful examination of the agar plates for
pinpoint colonies after 3 days of incubation would help ﬁnd sVISA.
Even stored culture of VISA strains may contain the original sVISA
strain as a minor subpopulation. In fact, we identiﬁed a few
pinpoint colonies on the drug-free agar plates streaked with the
glycerol stocks of 3 of the 33 VISA clinical strains listed in Table 1.
Table 3
Comparison of four categories of methicillin-resistant Staphylococcus aureus (MRSA) strains.
Category
of MRSA
Representative
strain
DT (in minutes)
(range)a
VAN
MIC
(mg/L)b (rangea)
Phenotypic reversion
after days of drug-free
passagec (rangea)
Genetic events underlying
the phenotyped
Cell wall
thickness (nm)
Autolysis
(% decrease
of OD)e
sVISA Mu3-6R-P 62.2 (43.3–133.3) 12 (8–24) 1 day (1–6) vraS(I5N), msrR(E146K),
rpoB(R512P)
26.1  2.6 11
VISA Mu50 37.1 (27.0–53.8) 12 (4–16) 30 days (20–84) vraS(I5N), msrR(E146K),
graR(N197S), rpoB(H481Y)
32.7  3.0 9
hVISA Mu3 36.1 3 >70 days vraS(I5N), msrR(E146K) 21.5  2.4 68
VSSA N315DIP 26.7 1 N/A None 16.4  2.9 91
VISA, vancomycin-intermediate S. aureus; sVISA, ‘slow VISA’; hVISA, hetero-VISA; DT, doubling time; VAN, vancomycin; MIC, minimum inhibitory concentration; N/A, not
applicable.
a Ranges of 26 sVISA laboratory strains and 16 VISA clinical strains.
b E-test using brain–heart infusion agar evaluated after 72 h of incubation.
c Different methods were used to evaluate stability of the resistance phenotype. For sVISA, the day of appearance of large colonies among the 107 CFU of culture was
determined. For VISA strains, the date of passage was determined when the vancomycin MIC came down to 2 mg/L. Mu3 stably maintained an MIC of 2 mg/L even after 70
days of propagation.
d Mutations of the representative strain are given.
e Triton X-100-induced autolysis of the representative strain. Percent decrease in the optical density (OD) at 660 nm after 3 h of incubation.
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expressed high and unstable vancomycin resistance as well as a
colony morphology similar to those observed with Mu3-6R-P
(Table 3). All of the strains lost the VISA phenotype and returned to
the large colony morphology within a week’s passage. This
indicated that generation of sVISA is not infrequent. They are
generated during vancomycin therapy but escaped recognition
since they easily reverted to hVISA or became stabilised as VISA
during propagation in the clinical laboratory. Generation of sVISA
during vancomycin therapy may well explain the discrepancy
between the frequency of vancomycin therapeutic failure and the
frequency of VISA isolation from patient samples.
6.2. Genetic mechanism of sVISA formation
Whole-genome sequencing of Mu3-6R-P revealed only one
single nucleotide polymorphism relative to the Mu3 genome.
The mutation was identiﬁed in the rpoB gene, changing theFig. 6. Instability of ‘slow VISA’ (sVISA) strain Mu3-6R-P. Heterogeneous colony
sizes observed in Mu3-6R-P. The strain with pinpoint colony morphology was
propagated for 2 days in drug-free medium. The culture was then spread on a drug-
free brain–heart infusion agar plate and incubated for 30 h. P, pinpoint colony; S,
small colony; L, large colony.arginine-512 to proline. Sequence determination of the rpoB gene
identiﬁed non-synonymous rpoB mutations in 7 (21%) of 28 sVISA
strains; they were rpoB(G744R), rpoB(S746F) (2 strains),
rpoB(H929T) (2 strains) and rpoB(G977V). Unlike the rpoB
mutations in extant VISA strains, these mutations were all
identiﬁed outside of the RRDR and, except for rpoB(R512P), were
located in the C-terminus half of the RpoB protein (Fig. 5).
Three Mu3-derived sVISA strains Mu3-6R-P, 17–6 d and 21–4 d
carrying rpoB(R512P), rpoB(S746F) and rpoB(H929T), respectively,
were cultivated in drug-free medium, and large-colony derivative
strains were established to determine their rpoB gene sequences.
The rpoB(H929T) mutation was back-mutated to wild-type and the
rpoB(R512P) mutation was replaced by alternate mutations such as
rpoB(R512L), rpoB(R512H) or rpoB(R512S). Only the rpoB(S746F)
mutation was not changed in three independently isolated large-
colony strains. All of the large-colony strains reverted to hVISA
phenotype with comparable levels of vancomycin resistance and
DTs to that of Mu3. Therefore, it is likely that certain rpoB mutation
does serve as an on-and-off switch for the sVISA phenotype.
A single mutation in the rpoB gene can make the cell survive
otherwise growth-inhibitory concentration of vancomycin. After
the vancomycin selective pressure is lifted, the bacteria can start to
diverge themselves beyond the constraints imposed by the rpoB
regulatory mutation. Some descendants can keep on maintaining
the VISA phenotype while slightly improving the severely
depressed growth rate by compensatory mutation. Others would
compromise a part of or the entire resistance phenotype for a much
faster growth rate through back-mutation of the affected nucleo-
tide, alternate mutation within the affected codon, or complemen-
tary mutation of the affected gene. In this way, rpoB mutation may
serve as a remarkable strategy for bacterial evolution to better
adapt to a changing environment.
7. Conclusion
In 2002, the ﬁrst clinical VRSA strain was isolated in Michigan,
USA [62]. This news ﬁlled people (including the authors [63]) with
apprehension that it might rapidly disseminate in hospitals all over
the world. However, so far only small numbers of VRSA isolation
have been reported. By reviewing the biological properties and
resistance mechanism of VISA and sVISA, the authors understand
why S. aureus does not need to acquire van genes from enterococci
by horizontal gene transfer. S. aureus appears to have already
conquered vancomycin as a threat to terminate its existence,
just as it dismissed b-lactam antibiotics half a century ago
by developing MRSA [64]. By its ingenious genetic strategies,
K. Hiramatsu et al. / Journal of Global Antimicrobial Resistance 2 (2014) 213–224 223S. aureus will continue to remain in human ﬂora as our tenacious
pathogen.
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